The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes

Experimental Cell Research

Volumn 313, Issue 11, 2007, Pages 2308-2317

  Scuoppo, Claudio ^a,b   Riess, Ilan ^a,b   Schmitt Ney, Michel ^a,b   Allegra, Paola ^b   Forni, Paolo E ^a,b   Bersani, Francesca ^a,b   Taulli, Riccardo ^a,b   Accornero, Paolo ^a,b   Crepaldi, Tiziana ^a,b   Ponzetto, Carola ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Alveolar rhabdomyosarcoma; Myogenesis; Pangene; PAX3 FKHR

Indexed keywords

TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; CYTODIAGNOSIS; FIBROBLAST; GENE REARRANGEMENT; MALIGNANT TRANSFORMATION; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TRANSCRIPTION REGULATION;

MURINAE;

EID: 34249992331     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.02.037     Document Type: Article

References (45)

1. Robson J., He S.J., and Eccles M.R. A PANorama of PAX genes in cancer and development. Nat. Rev., Cancer 6 (2006) 52-62
2. Dahl E., Koseki H., and Balling R. Pax genes and organogenesis. BioEssays 19 (1997) 755-765
3. Tajbakhsh S., Rocancourt D., Cossu G., and Buckingham M. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89 (1997) 127-138
4. Bajard L., Relaix F., Lagha M., Rocancourt D., Daubas P., and Buckingham M.E. A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates Myf5 in muscle progenitor cells in the limb. Genes Dev. 20 (2006) 2450-2464
5. Franz T., Kothary R., Surani M.A., Halata Z., and Grim M. The Splotch mutation interferes with muscle development in the limbs. Anat. Embryol. 187 (1993) 153-160
6. Bober E., Franz T., Arnold H.H., Gruss P., and Tremblay P. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development 120 (1994) 603-612
7. Goulding M., Lumsden A., and Paquette A.J. Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. Development 120 (1994) 957-971
8. Epstein D.J., Vekemans M., and Gros P. Splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3. Cell 67 (1991) 767-774
9. Borycki A.G., Li J., Jin F., Emerson C.P., and Epstein J.A. Pax3 functions in cell survival and in Pax7 regulation. Development 126 (1999) 1665-1674
10. Mansouri A., Stoykova A., Torres M., and Gruss P. Dysgenesis of cephalic neural crest Pax7-/- mutant mice. Development 122 (1996) 831-838
11. Oustanina S., Hause G., and Braun T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. EMBO J. 23 (2004) 3430-3439
12. Barr F.G., Galili N., Holick J., Biegel J.A., Rovera G., and Emanuel B.S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 3 (1993) 113-117
13. Accili D., and Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 (2004) 421-426
14. Fredericks W.J., Galili N., Mukhopadhyay S., Rovera G., Bennicelli J., Barr F.G., and Rauscher III F.J. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15 (1995) 1522-1535
15. Bennicelli J.L., Edwards R.H., and Barr F.G. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5455-5459
16. Nabarro S., Himoudi N., Papanastasiou A., Gilmour K., Gibson S., Sebire N., Thrasher A., Blundell M.P., Hubank M., Canderan G., and Anderson J. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J. Exp. Med. 202 (2005) 1399-1410
17. Begum S., Emani N., Cheung A., Wilkins O., Der S., and Hamel P.A. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 24 (2005) 1860-1872
18. Zhang L., and Wang C. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene 26 (2007) 1592-1605
19. Scheidler S., Fredericks W.J., Rauscher III F.J., Barr F.G., and Vogt P.K. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9805-9809
20. Lam P.Y., Sublett J.E., Hollenbach A.D., and Roussel M.F. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol. Cell. Biol. 19 (1999) 594-601
21. Keller C., Arenkiel B.R., Coffin C.M., El Bardeesy N., DePinho R.A., and Capecchi M.R. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18 (2004) 2614-2626
22. Margue C.M., Bernasconi M., Barr F.G., and Schafer B.W. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene 19 (2000) 2921-2929
23. Zhang L., and Wang C. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression. J. Biol. Chem. 278 (2003) 27-36
24. Relaix F., Polimeni M., Rocancourt D., Ponzetto C., Schafer B.W., and Buckingham M. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 17 (2003) 2950-2965
25. Taulli R., Scuoppo C., Bersani F., Accornero P., Forni P.E., Miretti S., Grinza A., Allegra P., Schmitt-Ney M., Crepaldi T., and Ponzetto C. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 66 (2006) 4742-4749
26. Xia S.J., and Barr F.G. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 23 (2004) 6864-6871
27. Khan J., Bittner M.L., Saal L.H., Teichmann U., Azorsa D.O., Gooden G.C., Pavan W.J., Trent J.M., and Meltzer P.S. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13264-13269
28. Epstein J.A., Lam P., Jepeal L., Maas R.L., and Shapiro D.N. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J. Biol. Chem. 270 (1995) 11719-11722
29. Todaro G.J., and Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17 (1963) 299-313
30. Parker M.H., Seale P., and Rudnicki M.A. Looking back to the embryo: defining transcriptional networks in adult myogenesis. Nat. Rev., Genet. 4 (2003) 497-507
31. Tapscott S.J., Davis R.L., Thayer M.J., Cheng P.F., Weintraub H., and Lassar A.B. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 242 (1988) 405-411
32. Braun T., Buschhausen-Denker G., Bober E., Tannich E., and Arnold H.H. A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. EMBO J. 8 (1989) 701-709
33. Braun T., Bober E., Winter B., Rosenthal N., and Arnold H.H. Myf-6, a new member of the human gene family of myogenic determination factors: evidence for a gene cluster on chromosome 12. EMBO J. 9 (1990) 821-831
34. Maroto M., Reshef R., Munsterberg A.E., Koester S., Goulding M., and Lassar A.B. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89 (1997) 139-148
35. Khan J., Bittner M.L., Saal L.H., Teichmann U., Azorsa D.O., Gooden G.C., Pavan W.J., Trent J.M., and Meltzer P.S. cDNA microarrays detect activation of a myogenic transcription program PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13264-13269
36. Lang D., Lu M.M., Huang L., Engleka K.A., Zhang M., Chu E.Y., Lipner S., Skoultchi A., Millar S.E., and Epstein J.A. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433 (2005) 884-887
37. Kempf B.E., and Vogt P.K. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma. Cell Growth Differ. 10 (1999) 813-818
38. Altmannsberger M., Weber K., Droste R., and Osborn M. Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am. J. Pathol. 118 (1985) 85-95
39. Sebire N.J., and Malone M. Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J. Clin. Pathol. 56 (2003) 412-416
40. Dias P., Chen B., Dilday B., Palmer H., Hosoi H., Singh S., Wu C., Li X., Thompson J., Parham D., Qualman S., and Houghton P. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am. J. Pathol. 156 (2000) 399-408
41. Hostein I., Andraud-Fregeville M., Guillou L., Terrier-Lacombe M.J., Deminiere C., Ranchere D., Lussan C., Longavenne E., Bui N.B., Delattre O., and Coindre J.M. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype. Cancer 101 (2004) 2817-2824
42. Tiffin N., Williams R.D., Shipley J., and Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 89 (2003) 327-332
43. Merlino G., and Helman L.J. Rhabdomyosarcoma-Working out the pathways. Oncogene 18 (1999) 5340-5348
44. Wang W., Slevin M., Kumar S., and Kumar P. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int. J. Oncol. 27 (2005) 1087-1096
45. Anderson J., Gordon A., Pritchard-Jones K., and Shipley J. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 26 (1999) 275-285